Related Experiment Video
Updated: Aug 23, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7
Mariam M Fakhry1,2, Kazem Mahmoud2, Mohamed S Nafie3
1Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
Abstract:
Breast cancer is a disease in which cells in the breast divide continuously without control. There are great limitations in cancer chemotherapy. Hence, it is essential to search for new cancer therapeutics. Herein, a novel series of EGFR/HER2 dual inhibitors has been designed based on the hybridization of thiazole and pyrazoline fragments. The synthesized compounds were screened for their anti-proliferative activity against MCF-7 breast cancer cell line and MCF-10 normal breast cell line. Interestingly, synthesized compounds 6e and 6k showed very potent antiproliferative activity towards MCF-7 with IC50 values of 7.21 and 8.02 µM, respectively. Furthermore, enzymatic assay was performed against EGFR and HER2 to prove the dual inhibitory action. Compounds 6e and 6k showed potent inhibitory activity for EGFR with IC50 of 0.009 and 0.051 µM, respectively, and for HER2 with IC50 of 0.013 and 0.027 µM, respectively. Additionally, compounds 6e and 6k significantly stimulated apoptotic breast cancer cell death. Compound 6e was further explored for its anticancer activity in vivo using a Xenograft model. Moreover, computational modeling studies, ADMET studies and toxicity prediction were performed to investigate their potential drug candidates.
Insights
Novel thiazole and pyrazoline compounds were developed as dual inhibitors of EGFR and HER2. Compounds 6e and 6k demonstrated potent antiproliferative effects against breast cancer cells, showing promise as new cancer therapeutics.
Area of Science:
- Medicinal Chemistry
- Oncology
- Drug Discovery
Background:
- Breast cancer chemotherapy faces significant limitations, necessitating the development of novel therapeutic agents.
- Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal growth factor Receptor 2 (HER2) is a validated strategy in breast cancer treatment.
Purpose of the Study:
- To design and synthesize a new series of dual EGFR/HER2 inhibitors based on thiazole and pyrazoline scaffolds.
- To evaluate the antiproliferative and apoptotic effects of synthesized compounds against breast cancer cell lines.
- To assess the in vivo efficacy and drug-likeness of lead compounds.
Main Methods:
- Hybridization of thiazole and pyrazoline fragments to create novel chemical entities.
- In vitro screening for antiproliferative activity against MCF-7 breast cancer and MCF-10 normal cell lines.
- Enzymatic assays to confirm EGFR and HER2 inhibitory potential.
- In vivo studies using a Xenograft breast cancer model.
- Computational modeling, ADMET, and toxicity predictions.
Main Results:
- Compounds 6e and 6k exhibited potent antiproliferative activity against MCF-7 cells (IC50 values of 7.21 and 8.02 µM).
- These compounds demonstrated significant dual inhibition of EGFR (IC50: 0.009 and 0.051 µM) and HER2 (IC50: 0.013 and 0.027 µM).
- Compounds 6e and 6k effectively induced apoptotic breast cancer cell death and showed promising in vivo anticancer activity.
Conclusions:
- The designed thiazole-pyrazoline hybrids represent a promising new class of dual EGFR/HER2 inhibitors for breast cancer therapy.
- Compounds 6e and 6k display excellent antiproliferative and apoptotic activities, warranting further investigation as potential drug candidates.
- Integrated computational and in vivo studies support the therapeutic potential of these novel breast cancer agents.
